Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

FDA to review Bristol Myers Squibb's Sotyktu for psoriatic arthritis

The FDA has set a target action date of 6 March 2026. This regulatory step follows similar acceptances in China and Japan, as well as an application validation The post FDA to review Bristol Myers Squibb’s Sotyktu for psoriatic arthritis appeared first on Pharmaceutical Business review.

FDA Accepts sNDA for Sotyktu in PsA

Bristol Myers Squibb's deucravacitinib gains global regulatory acceptance for treating active psoriatic arthritis, promising a new oral treatment option.